- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - 666-888-0000
- info@tersanpharm.com
- info@tersanpharm.com
- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - Contact Us
May2023
Tersan Pharmaceuticals Ltd continues to bolster Scientific Advisory Board by adding world-leading Oncologist Pr. Jean-Yves BLAY
Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Tersan routinely collects and combines clinical data with omic data, immunological […]
Mar2023
Tersan Pharmaceuticals Ltd strengthens SAB with appointment of world-leading Neurologist Jacques Touchon
Cambridge, MA, USA and Paris, France, March 27, 2023 – Tersan Pharmaceuticals Ltd, the leading Al-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.
Nov2022
CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials
• Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
• CY6463 favorable tolerability and safety profile was confirmed
Oct2022
AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX®2-73) in restoring key neurodegenerative pathways
Blarcamesine significantly restores functionality in key molecular pathways including Alzheimer’s and Parkinson’s disease, KEM® xAI analysis shows. Cambridge, MA, USA and Paris, France, October 4th, 2022 – Tersan Pharmaceuticals Ltd, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical […]
Jul2022
Tersan Pharmaceuticals Ltd strengthens management team with appointments of VP Business Development and Chief Financial Officer
Paris, France and Cambridge, MA, USA, July 26th, 2022 – Tersan Pharmaceuticals Ltd, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Tersan’s accelerated growth. […]
Jun2022
Tersan Pharmaceuticals Ltd, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Paris and Cambridge, MA, June 15th 2022. Tersan Pharmaceuticals Ltd and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Tersan Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]
Mar2022
Anavex Life Sciences and Tersan Pharmaceuticals Ltd present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference
Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Tersan, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.
Feb2022
Cyclerion Therapeutics and Tersan Pharmaceuticals Ltd Announce an Artificial Intelligence-driven Precision Medicine Collaboration
Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment
May2021
Tersan appoints pharmaceutical industry drug development veteran
Prior to joining Ariana, Hichem was Director of Development Operations at Sanofi. Hichem’s significant achievements encompass multiple therapeutic areas
May2021
Tersan announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi
The ATRACTion project will generate clinical, multi-omic (single cell RNA expression, gut microbiota) and additional immunological data by investigating several auto-immune diseases.